nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—IGF1R—type 2 diabetes mellitus	0.247	0.57	CbGaD
Crizotinib—SRC—type 2 diabetes mellitus	0.149	0.345	CbGaD
Crizotinib—CYP3A4—type 2 diabetes mellitus	0.0367	0.0848	CbGaD
Crizotinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.015	0.114	CbGbCtD
Crizotinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0133	0.102	CbGbCtD
Crizotinib—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0112	0.0857	CbGbCtD
Crizotinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00965	0.0736	CbGbCtD
Crizotinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00897	0.0684	CbGbCtD
Crizotinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.008	0.061	CbGbCtD
Crizotinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00731	0.0558	CbGbCtD
Crizotinib—CYP3A5—Losartan—type 2 diabetes mellitus	0.00694	0.0529	CbGbCtD
Crizotinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00663	0.0506	CbGbCtD
Crizotinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00639	0.0488	CbGbCtD
Crizotinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00578	0.0441	CbGbCtD
Crizotinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00494	0.0377	CbGbCtD
Crizotinib—ABCB1—Losartan—type 2 diabetes mellitus	0.00452	0.0345	CbGbCtD
Crizotinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00438	0.0334	CbGbCtD
Crizotinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0042	0.032	CbGbCtD
Crizotinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0042	0.032	CbGbCtD
Crizotinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00397	0.0303	CbGbCtD
Crizotinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00296	0.0226	CbGbCtD
Crizotinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00271	0.0206	CbGbCtD
Crizotinib—TESK1—Enalapril—Nateglinide—type 2 diabetes mellitus	0.0012	0.527	CbGdCrCtD
Crizotinib—TESK1—Enalapril—Ramipril—type 2 diabetes mellitus	0.000727	0.32	CbGdCrCtD
Crizotinib—MET—pancreas—type 2 diabetes mellitus	0.000511	0.00489	CbGeAlD
Crizotinib—NUAK2—islet of Langerhans—type 2 diabetes mellitus	0.000509	0.00488	CbGeAlD
Crizotinib—EPHA5—retina—type 2 diabetes mellitus	0.000508	0.00487	CbGeAlD
Crizotinib—ACVR1—islet of Langerhans—type 2 diabetes mellitus	0.000505	0.00484	CbGeAlD
Crizotinib—MAP4K1—retina—type 2 diabetes mellitus	0.000498	0.00477	CbGeAlD
Crizotinib—STK35—islet of Langerhans—type 2 diabetes mellitus	0.000495	0.00474	CbGeAlD
Crizotinib—MAPK7—adipose tissue—type 2 diabetes mellitus	0.000495	0.00474	CbGeAlD
Crizotinib—FES—adipose tissue—type 2 diabetes mellitus	0.00049	0.0047	CbGeAlD
Crizotinib—ACVR1B—kidney—type 2 diabetes mellitus	0.000475	0.00455	CbGeAlD
Crizotinib—ACVR1B—pancreas—type 2 diabetes mellitus	0.000472	0.00452	CbGeAlD
Crizotinib—MET—adipose tissue—type 2 diabetes mellitus	0.000463	0.00444	CbGeAlD
Crizotinib—RIPK2—islet of Langerhans—type 2 diabetes mellitus	0.000456	0.00437	CbGeAlD
Crizotinib—CDK7—adipose tissue—type 2 diabetes mellitus	0.000448	0.00429	CbGeAlD
Crizotinib—MERTK—retina—type 2 diabetes mellitus	0.000446	0.00428	CbGeAlD
Crizotinib—TAOK2—adipose tissue—type 2 diabetes mellitus	0.000445	0.00426	CbGeAlD
Crizotinib—TESK1—nephron tubule—type 2 diabetes mellitus	0.000432	0.00414	CbGeAlD
Crizotinib—ACVR1—retina—type 2 diabetes mellitus	0.000432	0.00414	CbGeAlD
Crizotinib—NEK9—liver—type 2 diabetes mellitus	0.000429	0.00411	CbGeAlD
Crizotinib—ACVR1B—adipose tissue—type 2 diabetes mellitus	0.000428	0.0041	CbGeAlD
Crizotinib—EPHA3—adipose tissue—type 2 diabetes mellitus	0.000428	0.0041	CbGeAlD
Crizotinib—TBK1—islet of Langerhans—type 2 diabetes mellitus	0.000424	0.00406	CbGeAlD
Crizotinib—PTK2—islet of Langerhans—type 2 diabetes mellitus	0.000424	0.00406	CbGeAlD
Crizotinib—TYK2—islet of Langerhans—type 2 diabetes mellitus	0.000421	0.00403	CbGeAlD
Crizotinib—IRAK1—islet of Langerhans—type 2 diabetes mellitus	0.000415	0.00398	CbGeAlD
Crizotinib—IGF1R—cardiovascular system—type 2 diabetes mellitus	0.000413	0.00396	CbGeAlD
Crizotinib—NUAK2—nephron tubule—type 2 diabetes mellitus	0.00041	0.00393	CbGeAlD
Crizotinib—FER—cortex of kidney—type 2 diabetes mellitus	0.00041	0.00392	CbGeAlD
Crizotinib—JAK3—adipose tissue—type 2 diabetes mellitus	0.000409	0.00392	CbGeAlD
Crizotinib—ACVR1—nephron tubule—type 2 diabetes mellitus	0.000407	0.0039	CbGeAlD
Crizotinib—DCLK1—adipose tissue—type 2 diabetes mellitus	0.000406	0.00389	CbGeAlD
Crizotinib—IGF1R—kidney—type 2 diabetes mellitus	0.000404	0.00387	CbGeAlD
Crizotinib—TIE1—cardiovascular system—type 2 diabetes mellitus	0.000402	0.00385	CbGeAlD
Crizotinib—IGF1R—pancreas—type 2 diabetes mellitus	0.000401	0.00385	CbGeAlD
Crizotinib—STK4—adipose tissue—type 2 diabetes mellitus	0.000401	0.00384	CbGeAlD
Crizotinib—RIPK2—retina—type 2 diabetes mellitus	0.00039	0.00374	CbGeAlD
Crizotinib—SLK—islet of Langerhans—type 2 diabetes mellitus	0.000388	0.00372	CbGeAlD
Crizotinib—EPHB4—islet of Langerhans—type 2 diabetes mellitus	0.000386	0.0037	CbGeAlD
Crizotinib—SIK2—liver—type 2 diabetes mellitus	0.000386	0.00369	CbGeAlD
Crizotinib—AURKA—kidney—type 2 diabetes mellitus	0.000383	0.00367	CbGeAlD
Crizotinib—STK3—cortex of kidney—type 2 diabetes mellitus	0.000383	0.00367	CbGeAlD
Crizotinib—FER—adipose tissue—type 2 diabetes mellitus	0.000379	0.00363	CbGeAlD
Crizotinib—EPHA2—islet of Langerhans—type 2 diabetes mellitus	0.000378	0.00363	CbGeAlD
Crizotinib—PRKD3—liver—type 2 diabetes mellitus	0.000376	0.0036	CbGeAlD
Crizotinib—BMPR1B—adipose tissue—type 2 diabetes mellitus	0.000371	0.00356	CbGeAlD
Crizotinib—MAP4K1—adipose tissue—type 2 diabetes mellitus	0.000371	0.00356	CbGeAlD
Crizotinib—TESK1—cortex of kidney—type 2 diabetes mellitus	0.00037	0.00355	CbGeAlD
Crizotinib—MAP4K5—islet of Langerhans—type 2 diabetes mellitus	0.000369	0.00354	CbGeAlD
Crizotinib—RIPK2—nephron tubule—type 2 diabetes mellitus	0.000368	0.00352	CbGeAlD
Crizotinib—FLT3—cardiovascular system—type 2 diabetes mellitus	0.000365	0.0035	CbGeAlD
Crizotinib—ACVR1—cardiovascular system—type 2 diabetes mellitus	0.000365	0.0035	CbGeAlD
Crizotinib—TNK2—adipose tissue—type 2 diabetes mellitus	0.000364	0.00349	CbGeAlD
Crizotinib—IGF1R—adipose tissue—type 2 diabetes mellitus	0.000364	0.00349	CbGeAlD
Crizotinib—TYK2—retina—type 2 diabetes mellitus	0.00036	0.00345	CbGeAlD
Crizotinib—MAP4K2—adipose tissue—type 2 diabetes mellitus	0.000359	0.00344	CbGeAlD
Crizotinib—CASK—liver—type 2 diabetes mellitus	0.000358	0.00343	CbGeAlD
Crizotinib—NUAK2—pancreas—type 2 diabetes mellitus	0.000358	0.00343	CbGeAlD
Crizotinib—ACVR1—kidney—type 2 diabetes mellitus	0.000358	0.00343	CbGeAlD
Crizotinib—ACVR1—pancreas—type 2 diabetes mellitus	0.000355	0.0034	CbGeAlD
Crizotinib—STK3—adipose tissue—type 2 diabetes mellitus	0.000354	0.00339	CbGeAlD
Crizotinib—TIE1—adipose tissue—type 2 diabetes mellitus	0.000354	0.00339	CbGeAlD
Crizotinib—EPHB6—islet of Langerhans—type 2 diabetes mellitus	0.000353	0.00338	CbGeAlD
Crizotinib—LIMK2—cortex of kidney—type 2 diabetes mellitus	0.000352	0.00337	CbGeAlD
Crizotinib—NUAK2—cortex of kidney—type 2 diabetes mellitus	0.000351	0.00336	CbGeAlD
Crizotinib—RPS6KB1—retina—type 2 diabetes mellitus	0.000349	0.00334	CbGeAlD
Crizotinib—MAP3K2—nephron tubule—type 2 diabetes mellitus	0.000348	0.00334	CbGeAlD
Crizotinib—ACVR1—cortex of kidney—type 2 diabetes mellitus	0.000348	0.00334	CbGeAlD
Crizotinib—STK35—pancreas—type 2 diabetes mellitus	0.000348	0.00333	CbGeAlD
Crizotinib—AURKA—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000346	0.153	CbGdCrCtD
Crizotinib—AXL—retina—type 2 diabetes mellitus	0.000345	0.00331	CbGeAlD
Crizotinib—FES—liver—type 2 diabetes mellitus	0.000344	0.00329	CbGeAlD
Crizotinib—TESK1—adipose tissue—type 2 diabetes mellitus	0.000342	0.00328	CbGeAlD
Crizotinib—PTK2—nephron tubule—type 2 diabetes mellitus	0.000341	0.00327	CbGeAlD
Crizotinib—TBK1—nephron tubule—type 2 diabetes mellitus	0.000341	0.00327	CbGeAlD
Crizotinib—YES1—islet of Langerhans—type 2 diabetes mellitus	0.000341	0.00327	CbGeAlD
Crizotinib—TYK2—nephron tubule—type 2 diabetes mellitus	0.000339	0.00325	CbGeAlD
Crizotinib—TAOK3—islet of Langerhans—type 2 diabetes mellitus	0.000337	0.00322	CbGeAlD
Crizotinib—IRAK1—nephron tubule—type 2 diabetes mellitus	0.000335	0.00321	CbGeAlD
Crizotinib—MERTK—adipose tissue—type 2 diabetes mellitus	0.000333	0.00319	CbGeAlD
Crizotinib—PTK2B—cardiovascular system—type 2 diabetes mellitus	0.000333	0.00319	CbGeAlD
Crizotinib—RIPK2—cardiovascular system—type 2 diabetes mellitus	0.00033	0.00316	CbGeAlD
Crizotinib—SRC—islet of Langerhans—type 2 diabetes mellitus	0.000328	0.00314	CbGeAlD
Crizotinib—LIMK2—adipose tissue—type 2 diabetes mellitus	0.000326	0.00312	CbGeAlD
Crizotinib—PTK2B—kidney—type 2 diabetes mellitus	0.000326	0.00312	CbGeAlD
Crizotinib—MET—liver—type 2 diabetes mellitus	0.000325	0.00311	CbGeAlD
Crizotinib—NUAK2—adipose tissue—type 2 diabetes mellitus	0.000325	0.00311	CbGeAlD
Crizotinib—MAP3K12—adipose tissue—type 2 diabetes mellitus	0.000322	0.00309	CbGeAlD
Crizotinib—ACVR1—adipose tissue—type 2 diabetes mellitus	0.000322	0.00309	CbGeAlD
Crizotinib—STK35—adipose tissue—type 2 diabetes mellitus	0.000316	0.00303	CbGeAlD
Crizotinib—CDK7—liver—type 2 diabetes mellitus	0.000314	0.00301	CbGeAlD
Crizotinib—SLK—nephron tubule—type 2 diabetes mellitus	0.000313	0.003	CbGeAlD
Crizotinib—TAOK2—liver—type 2 diabetes mellitus	0.000312	0.00299	CbGeAlD
Crizotinib—EPHB4—nephron tubule—type 2 diabetes mellitus	0.000311	0.00298	CbGeAlD
Crizotinib—ABL2—adipose tissue—type 2 diabetes mellitus	0.000308	0.00295	CbGeAlD
Crizotinib—TBK1—cardiovascular system—type 2 diabetes mellitus	0.000306	0.00294	CbGeAlD
Crizotinib—PTK2—cardiovascular system—type 2 diabetes mellitus	0.000306	0.00294	CbGeAlD
Crizotinib—EPHA2—nephron tubule—type 2 diabetes mellitus	0.000305	0.00292	CbGeAlD
Crizotinib—TYK2—cardiovascular system—type 2 diabetes mellitus	0.000304	0.00292	CbGeAlD
Crizotinib—BMP2K—adipose tissue—type 2 diabetes mellitus	0.000304	0.00291	CbGeAlD
Crizotinib—ACVR1B—liver—type 2 diabetes mellitus	0.0003	0.00288	CbGeAlD
Crizotinib—TBK1—kidney—type 2 diabetes mellitus	0.0003	0.00287	CbGeAlD
Crizotinib—PTK2—kidney—type 2 diabetes mellitus	0.0003	0.00287	CbGeAlD
Crizotinib—PTK2—pancreas—type 2 diabetes mellitus	0.000298	0.00285	CbGeAlD
Crizotinib—TBK1—pancreas—type 2 diabetes mellitus	0.000298	0.00285	CbGeAlD
Crizotinib—TYK2—kidney—type 2 diabetes mellitus	0.000298	0.00285	CbGeAlD
Crizotinib—MAP3K3—nephron tubule—type 2 diabetes mellitus	0.000297	0.00285	CbGeAlD
Crizotinib—TYK2—pancreas—type 2 diabetes mellitus	0.000296	0.00284	CbGeAlD
Crizotinib—RPS6KB1—cardiovascular system—type 2 diabetes mellitus	0.000295	0.00283	CbGeAlD
Crizotinib—PTK2B—adipose tissue—type 2 diabetes mellitus	0.000294	0.00281	CbGeAlD
Crizotinib—FGR—cardiovascular system—type 2 diabetes mellitus	0.000293	0.00281	CbGeAlD
Crizotinib—PTK2—cortex of kidney—type 2 diabetes mellitus	0.000292	0.0028	CbGeAlD
Crizotinib—TBK1—cortex of kidney—type 2 diabetes mellitus	0.000292	0.0028	CbGeAlD
Crizotinib—IRAK1—pancreas—type 2 diabetes mellitus	0.000292	0.0028	CbGeAlD
Crizotinib—AXL—cardiovascular system—type 2 diabetes mellitus	0.000292	0.0028	CbGeAlD
Crizotinib—YES1—retina—type 2 diabetes mellitus	0.000291	0.00279	CbGeAlD
Crizotinib—RIPK2—adipose tissue—type 2 diabetes mellitus	0.000291	0.00279	CbGeAlD
Crizotinib—TYK2—cortex of kidney—type 2 diabetes mellitus	0.00029	0.00278	CbGeAlD
Crizotinib—RPS6KB1—kidney—type 2 diabetes mellitus	0.000288	0.00276	CbGeAlD
Crizotinib—TAOK3—retina—type 2 diabetes mellitus	0.000288	0.00276	CbGeAlD
Crizotinib—RPS6KB1—pancreas—type 2 diabetes mellitus	0.000287	0.00275	CbGeAlD
Crizotinib—IRAK1—cortex of kidney—type 2 diabetes mellitus	0.000286	0.00274	CbGeAlD
Crizotinib—EPHA4—adipose tissue—type 2 diabetes mellitus	0.000281	0.0027	CbGeAlD
Crizotinib—STK4—liver—type 2 diabetes mellitus	0.000281	0.0027	CbGeAlD
Crizotinib—RPS6KB1—cortex of kidney—type 2 diabetes mellitus	0.000281	0.00269	CbGeAlD
Crizotinib—SRC—retina—type 2 diabetes mellitus	0.00028	0.00269	CbGeAlD
Crizotinib—EPHB4—cardiovascular system—type 2 diabetes mellitus	0.000279	0.00267	CbGeAlD
Crizotinib—AXL—cortex of kidney—type 2 diabetes mellitus	0.000278	0.00267	CbGeAlD
Crizotinib—JAK2—cardiovascular system—type 2 diabetes mellitus	0.000277	0.00265	CbGeAlD
Crizotinib—MAP3K2—adipose tissue—type 2 diabetes mellitus	0.000276	0.00264	CbGeAlD
Crizotinib—YES1—nephron tubule—type 2 diabetes mellitus	0.000274	0.00263	CbGeAlD
Crizotinib—EPHA2—cardiovascular system—type 2 diabetes mellitus	0.000274	0.00262	CbGeAlD
Crizotinib—SLK—pancreas—type 2 diabetes mellitus	0.000273	0.00262	CbGeAlD
Crizotinib—EPHB4—kidney—type 2 diabetes mellitus	0.000273	0.00262	CbGeAlD
Crizotinib—EPHB4—pancreas—type 2 diabetes mellitus	0.000271	0.0026	CbGeAlD
Crizotinib—JAK2—kidney—type 2 diabetes mellitus	0.000271	0.0026	CbGeAlD
Crizotinib—TAOK3—nephron tubule—type 2 diabetes mellitus	0.000271	0.0026	CbGeAlD
Crizotinib—TBK1—adipose tissue—type 2 diabetes mellitus	0.00027	0.00259	CbGeAlD
Crizotinib—PTK2—adipose tissue—type 2 diabetes mellitus	0.00027	0.00259	CbGeAlD
Crizotinib—TYK2—adipose tissue—type 2 diabetes mellitus	0.000268	0.00257	CbGeAlD
Crizotinib—SLK—cortex of kidney—type 2 diabetes mellitus	0.000268	0.00257	CbGeAlD
Crizotinib—TEK—cardiovascular system—type 2 diabetes mellitus	0.000267	0.00256	CbGeAlD
Crizotinib—MAP3K3—cardiovascular system—type 2 diabetes mellitus	0.000267	0.00256	CbGeAlD
Crizotinib—EPHA2—pancreas—type 2 diabetes mellitus	0.000266	0.00255	CbGeAlD
Crizotinib—FER—liver—type 2 diabetes mellitus	0.000266	0.00255	CbGeAlD
Crizotinib—EPHB4—cortex of kidney—type 2 diabetes mellitus	0.000266	0.00255	CbGeAlD
Crizotinib—IRAK1—adipose tissue—type 2 diabetes mellitus	0.000265	0.00254	CbGeAlD
Crizotinib—LYN—liver—type 2 diabetes mellitus	0.000264	0.00253	CbGeAlD
Crizotinib—JAK2—cortex of kidney—type 2 diabetes mellitus	0.000264	0.00253	CbGeAlD
Crizotinib—TNK1—liver—type 2 diabetes mellitus	0.000263	0.00252	CbGeAlD
Crizotinib—TEK—kidney—type 2 diabetes mellitus	0.000261	0.0025	CbGeAlD
Crizotinib—RPS6KB1—adipose tissue—type 2 diabetes mellitus	0.00026	0.00249	CbGeAlD
Crizotinib—MAP4K5—pancreas—type 2 diabetes mellitus	0.000259	0.00249	CbGeAlD
Crizotinib—TEK—pancreas—type 2 diabetes mellitus	0.000259	0.00249	CbGeAlD
Crizotinib—LCK—adipose tissue—type 2 diabetes mellitus	0.000258	0.00248	CbGeAlD
Crizotinib—FGR—adipose tissue—type 2 diabetes mellitus	0.000258	0.00248	CbGeAlD
Crizotinib—AXL—adipose tissue—type 2 diabetes mellitus	0.000257	0.00247	CbGeAlD
Crizotinib—IGF1R—liver—type 2 diabetes mellitus	0.000255	0.00245	CbGeAlD
Crizotinib—TNK2—liver—type 2 diabetes mellitus	0.000255	0.00245	CbGeAlD
Crizotinib—MAP4K5—cortex of kidney—type 2 diabetes mellitus	0.000254	0.00244	CbGeAlD
Crizotinib—MAP3K3—cortex of kidney—type 2 diabetes mellitus	0.000254	0.00244	CbGeAlD
Crizotinib—TEK—cortex of kidney—type 2 diabetes mellitus	0.000254	0.00244	CbGeAlD
Crizotinib—MAP4K2—liver—type 2 diabetes mellitus	0.000252	0.00241	CbGeAlD
Crizotinib—TIE1—liver—type 2 diabetes mellitus	0.000248	0.00238	CbGeAlD
Crizotinib—STK3—liver—type 2 diabetes mellitus	0.000248	0.00238	CbGeAlD
Crizotinib—SLK—adipose tissue—type 2 diabetes mellitus	0.000248	0.00237	CbGeAlD
Crizotinib—EPHB4—adipose tissue—type 2 diabetes mellitus	0.000246	0.00236	CbGeAlD
Crizotinib—STK10—cardiovascular system—type 2 diabetes mellitus	0.000244	0.00234	CbGeAlD
Crizotinib—JAK2—adipose tissue—type 2 diabetes mellitus	0.000244	0.00234	CbGeAlD
Crizotinib—TAOK3—cardiovascular system—type 2 diabetes mellitus	0.000243	0.00233	CbGeAlD
Crizotinib—EPHB6—cortex of kidney—type 2 diabetes mellitus	0.000243	0.00233	CbGeAlD
Crizotinib—AURKA—liver—type 2 diabetes mellitus	0.000242	0.00232	CbGeAlD
Crizotinib—EPHA2—adipose tissue—type 2 diabetes mellitus	0.000241	0.00231	CbGeAlD
Crizotinib—YES1—kidney—type 2 diabetes mellitus	0.000241	0.00231	CbGeAlD
Crizotinib—TESK1—liver—type 2 diabetes mellitus	0.00024	0.0023	CbGeAlD
Crizotinib—YES1—pancreas—type 2 diabetes mellitus	0.00024	0.0023	CbGeAlD
Crizotinib—STK10—kidney—type 2 diabetes mellitus	0.000239	0.00229	CbGeAlD
Crizotinib—TAOK3—kidney—type 2 diabetes mellitus	0.000238	0.00228	CbGeAlD
Crizotinib—SRC—cardiovascular system—type 2 diabetes mellitus	0.000237	0.00227	CbGeAlD
Crizotinib—TAOK3—pancreas—type 2 diabetes mellitus	0.000237	0.00227	CbGeAlD
Crizotinib—MAP4K5—adipose tissue—type 2 diabetes mellitus	0.000235	0.00226	CbGeAlD
Crizotinib—MAP3K3—adipose tissue—type 2 diabetes mellitus	0.000235	0.00226	CbGeAlD
Crizotinib—TEK—adipose tissue—type 2 diabetes mellitus	0.000235	0.00226	CbGeAlD
Crizotinib—YES1—cortex of kidney—type 2 diabetes mellitus	0.000235	0.00225	CbGeAlD
Crizotinib—MERTK—liver—type 2 diabetes mellitus	0.000234	0.00224	CbGeAlD
Crizotinib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.000233	0.00223	CbGeAlD
Crizotinib—SRC—kidney—type 2 diabetes mellitus	0.000232	0.00222	CbGeAlD
Crizotinib—TAOK3—cortex of kidney—type 2 diabetes mellitus	0.000232	0.00222	CbGeAlD
Crizotinib—SRC—pancreas—type 2 diabetes mellitus	0.000231	0.00221	CbGeAlD
Crizotinib—LIMK2—liver—type 2 diabetes mellitus	0.000228	0.00219	CbGeAlD
Crizotinib—NUAK2—liver—type 2 diabetes mellitus	0.000228	0.00218	CbGeAlD
Crizotinib—MAP3K12—liver—type 2 diabetes mellitus	0.000226	0.00217	CbGeAlD
Crizotinib—ACVR1—liver—type 2 diabetes mellitus	0.000226	0.00217	CbGeAlD
Crizotinib—FLT3—liver—type 2 diabetes mellitus	0.000226	0.00217	CbGeAlD
Crizotinib—EPHB6—adipose tissue—type 2 diabetes mellitus	0.000225	0.00216	CbGeAlD
Crizotinib—STK35—liver—type 2 diabetes mellitus	0.000221	0.00212	CbGeAlD
Crizotinib—YES1—adipose tissue—type 2 diabetes mellitus	0.000217	0.00208	CbGeAlD
Crizotinib—ABL2—liver—type 2 diabetes mellitus	0.000216	0.00207	CbGeAlD
Crizotinib—STK10—adipose tissue—type 2 diabetes mellitus	0.000215	0.00206	CbGeAlD
Crizotinib—TAOK3—adipose tissue—type 2 diabetes mellitus	0.000215	0.00206	CbGeAlD
Crizotinib—BMP2K—liver—type 2 diabetes mellitus	0.000213	0.00204	CbGeAlD
Crizotinib—CSF1R—cardiovascular system—type 2 diabetes mellitus	0.000213	0.00204	CbGeAlD
Crizotinib—SRC—adipose tissue—type 2 diabetes mellitus	0.000209	0.002	CbGeAlD
Crizotinib—PTK2B—liver—type 2 diabetes mellitus	0.000206	0.00197	CbGeAlD
Crizotinib—RIPK2—liver—type 2 diabetes mellitus	0.000204	0.00196	CbGeAlD
Crizotinib—ABL1—retina—type 2 diabetes mellitus	0.000199	0.00191	CbGeAlD
Crizotinib—MAP3K2—liver—type 2 diabetes mellitus	0.000194	0.00185	CbGeAlD
Crizotinib—TBK1—liver—type 2 diabetes mellitus	0.00019	0.00182	CbGeAlD
Crizotinib—PTK2—liver—type 2 diabetes mellitus	0.00019	0.00182	CbGeAlD
Crizotinib—TYK2—liver—type 2 diabetes mellitus	0.000188	0.0018	CbGeAlD
Crizotinib—CSF1R—adipose tissue—type 2 diabetes mellitus	0.000188	0.0018	CbGeAlD
Crizotinib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000187	0.0018	CbGeAlD
Crizotinib—IRAK1—liver—type 2 diabetes mellitus	0.000186	0.00178	CbGeAlD
Crizotinib—Malnutrition—Valsartan—type 2 diabetes mellitus	0.000185	0.00127	CcSEcCtD
Crizotinib—Oedema—Glyburide—type 2 diabetes mellitus	0.000183	0.00126	CcSEcCtD
Crizotinib—Malnutrition—Orlistat—type 2 diabetes mellitus	0.000183	0.00126	CcSEcCtD
Crizotinib—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000183	0.00126	CcSEcCtD
Crizotinib—RPS6KB1—liver—type 2 diabetes mellitus	0.000182	0.00175	CbGeAlD
Crizotinib—Hypoaesthesia—Irbesartan—type 2 diabetes mellitus	0.000182	0.00125	CcSEcCtD
Crizotinib—Rash—Repaglinide—type 2 diabetes mellitus	0.000182	0.00125	CcSEcCtD
Crizotinib—Dysgeusia—Valsartan—type 2 diabetes mellitus	0.000182	0.00125	CcSEcCtD
Crizotinib—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000182	0.00125	CcSEcCtD
Crizotinib—Eye disorder—Metformin—type 2 diabetes mellitus	0.000181	0.00124	CcSEcCtD
Crizotinib—FGR—liver—type 2 diabetes mellitus	0.000181	0.00174	CbGeAlD
Crizotinib—LCK—liver—type 2 diabetes mellitus	0.000181	0.00174	CbGeAlD
Crizotinib—Urinary tract disorder—Irbesartan—type 2 diabetes mellitus	0.000181	0.00124	CcSEcCtD
Crizotinib—Leukopenia—Gliclazide—type 2 diabetes mellitus	0.000181	0.00124	CcSEcCtD
Crizotinib—Shock—Glyburide—type 2 diabetes mellitus	0.000181	0.00124	CcSEcCtD
Crizotinib—AXL—liver—type 2 diabetes mellitus	0.00018	0.00173	CbGeAlD
Crizotinib—Oedema peripheral—Irbesartan—type 2 diabetes mellitus	0.00018	0.00124	CcSEcCtD
Crizotinib—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	0.00018	0.00124	CcSEcCtD
Crizotinib—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00018	0.00124	CcSEcCtD
Crizotinib—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.00018	0.00124	CcSEcCtD
Crizotinib—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.00018	0.00123	CcSEcCtD
Crizotinib—Urethral disorder—Irbesartan—type 2 diabetes mellitus	0.000179	0.00123	CcSEcCtD
Crizotinib—Dysgeusia—Orlistat—type 2 diabetes mellitus	0.000179	0.00123	CcSEcCtD
Crizotinib—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000179	0.00123	CcSEcCtD
Crizotinib—Loss of consciousness—Gliclazide—type 2 diabetes mellitus	0.000177	0.00122	CcSEcCtD
Crizotinib—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000177	0.00121	CcSEcCtD
Crizotinib—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000176	0.00121	CcSEcCtD
Crizotinib—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.000175	0.0012	CcSEcCtD
Crizotinib—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000175	0.0012	CcSEcCtD
Crizotinib—Decreased appetite—Bromocriptine—type 2 diabetes mellitus	0.000174	0.0012	CcSEcCtD
Crizotinib—SLK—liver—type 2 diabetes mellitus	0.000174	0.00167	CbGeAlD
Crizotinib—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000173	0.00119	CcSEcCtD
Crizotinib—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000173	0.00119	CcSEcCtD
Crizotinib—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000173	0.00119	CcSEcCtD
Crizotinib—Neutropenia—Ramipril—type 2 diabetes mellitus	0.000173	0.00118	CcSEcCtD
Crizotinib—EPHB4—liver—type 2 diabetes mellitus	0.000172	0.00165	CbGeAlD
Crizotinib—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000172	0.00118	CcSEcCtD
Crizotinib—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000172	0.00118	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	0.000172	0.00118	CcSEcCtD
Crizotinib—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000172	0.00118	CcSEcCtD
Crizotinib—Hypoaesthesia—Losartan—type 2 diabetes mellitus	0.000171	0.00118	CcSEcCtD
Crizotinib—JAK2—liver—type 2 diabetes mellitus	0.000171	0.00164	CbGeAlD
Crizotinib—Nausea—Repaglinide—type 2 diabetes mellitus	0.000171	0.00117	CcSEcCtD
Crizotinib—Asthenia—Glipizide—type 2 diabetes mellitus	0.000171	0.00117	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000171	0.00117	CcSEcCtD
Crizotinib—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.00017	0.00117	CcSEcCtD
Crizotinib—EPHA2—liver—type 2 diabetes mellitus	0.000169	0.00162	CbGeAlD
Crizotinib—Malnutrition—Metformin—type 2 diabetes mellitus	0.000169	0.00116	CcSEcCtD
Crizotinib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000168	0.00161	CbGeAlD
Crizotinib—Syncope—Valsartan—type 2 diabetes mellitus	0.000166	0.00114	CcSEcCtD
Crizotinib—Dysgeusia—Metformin—type 2 diabetes mellitus	0.000165	0.00113	CcSEcCtD
Crizotinib—TEK—liver—type 2 diabetes mellitus	0.000165	0.00158	CbGeAlD
Crizotinib—MAP3K3—liver—type 2 diabetes mellitus	0.000165	0.00158	CbGeAlD
Crizotinib—MAP4K5—liver—type 2 diabetes mellitus	0.000165	0.00158	CbGeAlD
Crizotinib—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000165	0.00113	CcSEcCtD
Crizotinib—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.000165	0.00113	CcSEcCtD
Crizotinib—ABL1—kidney—type 2 diabetes mellitus	0.000165	0.00158	CbGeAlD
Crizotinib—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000164	0.00112	CcSEcCtD
Crizotinib—Infection—Gliclazide—type 2 diabetes mellitus	0.000164	0.00112	CcSEcCtD
Crizotinib—ABL1—pancreas—type 2 diabetes mellitus	0.000164	0.00157	CbGeAlD
Crizotinib—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000164	0.00112	CcSEcCtD
Crizotinib—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000164	0.00112	CcSEcCtD
Crizotinib—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000163	0.00112	CcSEcCtD
Crizotinib—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.000163	0.00112	CcSEcCtD
Crizotinib—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000162	0.00111	CcSEcCtD
Crizotinib—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000162	0.00111	CcSEcCtD
Crizotinib—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000162	0.00111	CcSEcCtD
Crizotinib—Neuropathy peripheral—Ramipril—type 2 diabetes mellitus	0.000161	0.00111	CcSEcCtD
Crizotinib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.00016	0.00154	CbGeAlD
Crizotinib—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00016	0.0011	CcSEcCtD
Crizotinib—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00016	0.0011	CcSEcCtD
Crizotinib—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.00016	0.00109	CcSEcCtD
Crizotinib—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000159	0.00109	CcSEcCtD
Crizotinib—Vision blurred—Metformin—type 2 diabetes mellitus	0.000159	0.00109	CcSEcCtD
Crizotinib—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000159	0.00109	CcSEcCtD
Crizotinib—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000159	0.00109	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000158	0.00109	CcSEcCtD
Crizotinib—Dizziness—Glipizide—type 2 diabetes mellitus	0.000158	0.00108	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000157	0.00108	CcSEcCtD
Crizotinib—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000156	0.00107	CcSEcCtD
Crizotinib—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000156	0.00107	CcSEcCtD
Crizotinib—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	0.000156	0.00107	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000155	0.00106	CcSEcCtD
Crizotinib—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000154	0.00106	CcSEcCtD
Crizotinib—YES1—liver—type 2 diabetes mellitus	0.000152	0.00146	CbGeAlD
Crizotinib—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000152	0.00104	CcSEcCtD
Crizotinib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000152	0.00104	CcSEcCtD
Crizotinib—Vomiting—Glipizide—type 2 diabetes mellitus	0.000152	0.00104	CcSEcCtD
Crizotinib—Syncope—Metformin—type 2 diabetes mellitus	0.000151	0.00104	CcSEcCtD
Crizotinib—Oedema—Valsartan—type 2 diabetes mellitus	0.000151	0.00104	CcSEcCtD
Crizotinib—STK10—liver—type 2 diabetes mellitus	0.000151	0.00145	CbGeAlD
Crizotinib—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000151	0.00104	CcSEcCtD
Crizotinib—TAOK3—liver—type 2 diabetes mellitus	0.000151	0.00144	CbGeAlD
Crizotinib—Infection—Valsartan—type 2 diabetes mellitus	0.00015	0.00103	CcSEcCtD
Crizotinib—Rash—Glipizide—type 2 diabetes mellitus	0.00015	0.00103	CcSEcCtD
Crizotinib—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.00015	0.00103	CcSEcCtD
Crizotinib—Dermatitis—Glipizide—type 2 diabetes mellitus	0.00015	0.00103	CcSEcCtD
Crizotinib—Oedema—Orlistat—type 2 diabetes mellitus	0.00015	0.00103	CcSEcCtD
Crizotinib—Shock—Valsartan—type 2 diabetes mellitus	0.000149	0.00102	CcSEcCtD
Crizotinib—Infection—Orlistat—type 2 diabetes mellitus	0.000149	0.00102	CcSEcCtD
Crizotinib—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000148	0.00102	CcSEcCtD
Crizotinib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000148	0.00102	CcSEcCtD
Crizotinib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000148	0.00142	CbGeAlD
Crizotinib—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000148	0.00102	CcSEcCtD
Crizotinib—Anaemia—Irbesartan—type 2 diabetes mellitus	0.000147	0.00101	CcSEcCtD
Crizotinib—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000147	0.00101	CcSEcCtD
Crizotinib—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000147	0.00101	CcSEcCtD
Crizotinib—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000147	0.00101	CcSEcCtD
Crizotinib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000147	0.00101	CcSEcCtD
Crizotinib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000147	0.00101	CcSEcCtD
Crizotinib—SRC—liver—type 2 diabetes mellitus	0.000147	0.00141	CbGeAlD
Crizotinib—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000147	0.00101	CcSEcCtD
Crizotinib—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000146	0.000999	CcSEcCtD
Crizotinib—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000145	0.000997	CcSEcCtD
Crizotinib—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000145	0.000995	CcSEcCtD
Crizotinib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000144	0.000988	CcSEcCtD
Crizotinib—Syncope—Irbesartan—type 2 diabetes mellitus	0.000143	0.000981	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000143	0.00098	CcSEcCtD
Crizotinib—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000143	0.000979	CcSEcCtD
Crizotinib—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000142	0.000977	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000142	0.000976	CcSEcCtD
Crizotinib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000142	0.000975	CcSEcCtD
Crizotinib—Nausea—Glipizide—type 2 diabetes mellitus	0.000142	0.000972	CcSEcCtD
Crizotinib—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000141	0.000971	CcSEcCtD
Crizotinib—Vision blurred—Losartan—type 2 diabetes mellitus	0.000141	0.00097	CcSEcCtD
Crizotinib—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000141	0.000967	CcSEcCtD
Crizotinib—Constipation—Gliclazide—type 2 diabetes mellitus	0.000141	0.000967	CcSEcCtD
Crizotinib—Rash—Glimepiride—type 2 diabetes mellitus	0.00014	0.000962	CcSEcCtD
Crizotinib—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.00014	0.000962	CcSEcCtD
Crizotinib—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.00014	0.000961	CcSEcCtD
Crizotinib—Rash—Sitagliptin—type 2 diabetes mellitus	0.00014	0.000959	CcSEcCtD
Crizotinib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.00014	0.000959	CcSEcCtD
Crizotinib—Anaemia—Losartan—type 2 diabetes mellitus	0.000139	0.000951	CcSEcCtD
Crizotinib—Oedema—Metformin—type 2 diabetes mellitus	0.000138	0.000946	CcSEcCtD
Crizotinib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000137	0.000942	CcSEcCtD
Crizotinib—Infection—Metformin—type 2 diabetes mellitus	0.000137	0.00094	CcSEcCtD
Crizotinib—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000136	0.00131	CbGeAlD
Crizotinib—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000136	0.000933	CcSEcCtD
Crizotinib—Shock—Metformin—type 2 diabetes mellitus	0.000136	0.00093	CcSEcCtD
Crizotinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000135	0.000927	CcSEcCtD
Crizotinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000135	0.000926	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000135	0.000925	CcSEcCtD
Crizotinib—Syncope—Losartan—type 2 diabetes mellitus	0.000135	0.000923	CcSEcCtD
Crizotinib—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000134	0.000921	CcSEcCtD
Crizotinib—Leukopenia—Losartan—type 2 diabetes mellitus	0.000134	0.000921	CcSEcCtD
Crizotinib—Skin disorder—Metformin—type 2 diabetes mellitus	0.000134	0.000919	CcSEcCtD
Crizotinib—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000133	0.000914	CcSEcCtD
Crizotinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000133	0.000914	CcSEcCtD
Crizotinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000133	0.000911	CcSEcCtD
Crizotinib—Nausea—Glimepiride—type 2 diabetes mellitus	0.000132	0.000907	CcSEcCtD
Crizotinib—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000132	0.000906	CcSEcCtD
Crizotinib—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000132	0.000905	CcSEcCtD
Crizotinib—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000132	0.000904	CcSEcCtD
Crizotinib—CSF1R—liver—type 2 diabetes mellitus	0.000132	0.00126	CbGeAlD
Crizotinib—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000132	0.000903	CcSEcCtD
Crizotinib—Asthenia—Glyburide—type 2 diabetes mellitus	0.000132	0.000903	CcSEcCtD
Crizotinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000132	0.000903	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000131	0.000897	CcSEcCtD
Crizotinib—Fatigue—Valsartan—type 2 diabetes mellitus	0.000131	0.000895	CcSEcCtD
Crizotinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.00013	0.000894	CcSEcCtD
Crizotinib—Oedema—Irbesartan—type 2 diabetes mellitus	0.00013	0.000892	CcSEcCtD
Crizotinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.00013	0.000892	CcSEcCtD
Crizotinib—Constipation—Valsartan—type 2 diabetes mellitus	0.000129	0.000888	CcSEcCtD
Crizotinib—Infection—Irbesartan—type 2 diabetes mellitus	0.000129	0.000887	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000129	0.000886	CcSEcCtD
Crizotinib—Fatigue—Orlistat—type 2 diabetes mellitus	0.000129	0.000885	CcSEcCtD
Crizotinib—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000129	0.000882	CcSEcCtD
Crizotinib—Shock—Irbesartan—type 2 diabetes mellitus	0.000128	0.000878	CcSEcCtD
Crizotinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000128	0.000876	CcSEcCtD
Crizotinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000128	0.000875	CcSEcCtD
Crizotinib—Rash—Bromocriptine—type 2 diabetes mellitus	0.000127	0.000868	CcSEcCtD
Crizotinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000126	0.000867	CcSEcCtD
Crizotinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000126	0.000867	CcSEcCtD
Crizotinib—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000126	0.000864	CcSEcCtD
Crizotinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000126	0.000861	CcSEcCtD
Crizotinib—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000124	0.000849	CcSEcCtD
Crizotinib—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000123	0.000843	CcSEcCtD
Crizotinib—Oedema—Losartan—type 2 diabetes mellitus	0.000122	0.00084	CcSEcCtD
Crizotinib—Infection—Losartan—type 2 diabetes mellitus	0.000122	0.000834	CcSEcCtD
Crizotinib—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000121	0.000832	CcSEcCtD
Crizotinib—Shock—Losartan—type 2 diabetes mellitus	0.00012	0.000826	CcSEcCtD
Crizotinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00012	0.000824	CcSEcCtD
Crizotinib—Decreased appetite—Metformin—type 2 diabetes mellitus	0.00012	0.000822	CcSEcCtD
Crizotinib—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000119	0.000818	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000119	0.000816	CcSEcCtD
Crizotinib—Fatigue—Metformin—type 2 diabetes mellitus	0.000119	0.000815	CcSEcCtD
Crizotinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000118	0.000811	CcSEcCtD
Crizotinib—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000118	0.000811	CcSEcCtD
Crizotinib—Constipation—Metformin—type 2 diabetes mellitus	0.000118	0.000809	CcSEcCtD
Crizotinib—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000117	0.000801	CcSEcCtD
Crizotinib—Vomiting—Glyburide—type 2 diabetes mellitus	0.000117	0.0008	CcSEcCtD
Crizotinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000116	0.000796	CcSEcCtD
Crizotinib—Rash—Glyburide—type 2 diabetes mellitus	0.000116	0.000794	CcSEcCtD
Crizotinib—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000116	0.000793	CcSEcCtD
Crizotinib—Syncope—Ramipril—type 2 diabetes mellitus	0.000115	0.000791	CcSEcCtD
Crizotinib—Leukopenia—Ramipril—type 2 diabetes mellitus	0.000115	0.00079	CcSEcCtD
Crizotinib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000115	0.000786	CcSEcCtD
Crizotinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000113	0.000776	CcSEcCtD
Crizotinib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000113	0.000776	CcSEcCtD
Crizotinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000113	0.000773	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000112	0.000771	CcSEcCtD
Crizotinib—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000112	0.000769	CcSEcCtD
Crizotinib—Constipation—Irbesartan—type 2 diabetes mellitus	0.000111	0.000763	CcSEcCtD
Crizotinib—Paraesthesia—Losartan—type 2 diabetes mellitus	0.00011	0.000754	CcSEcCtD
Crizotinib—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.00011	0.00105	CbGeAlD
Crizotinib—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000109	0.000749	CcSEcCtD
Crizotinib—Nausea—Glyburide—type 2 diabetes mellitus	0.000109	0.000748	CcSEcCtD
Crizotinib—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000109	0.000747	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000109	0.000746	CcSEcCtD
Crizotinib—Asthenia—Valsartan—type 2 diabetes mellitus	0.000109	0.000745	CcSEcCtD
Crizotinib—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000108	0.000739	CcSEcCtD
Crizotinib—Asthenia—Orlistat—type 2 diabetes mellitus	0.000107	0.000736	CcSEcCtD
Crizotinib—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000106	0.00073	CcSEcCtD
Crizotinib—Fatigue—Losartan—type 2 diabetes mellitus	0.000106	0.000724	CcSEcCtD
Crizotinib—Oedema—Ramipril—type 2 diabetes mellitus	0.000105	0.00072	CcSEcCtD
Crizotinib—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000105	0.000719	CcSEcCtD
Crizotinib—Constipation—Losartan—type 2 diabetes mellitus	0.000105	0.000718	CcSEcCtD
Crizotinib—ABL1—liver—type 2 diabetes mellitus	0.000104	0.000998	CbGeAlD
Crizotinib—Rash—Gliclazide—type 2 diabetes mellitus	0.000104	0.000713	CcSEcCtD
Crizotinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000104	0.000712	CcSEcCtD
Crizotinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000104	0.000711	CcSEcCtD
Crizotinib—Shock—Ramipril—type 2 diabetes mellitus	0.000103	0.000709	CcSEcCtD
Crizotinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000103	0.000706	CcSEcCtD
Crizotinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000103	0.000706	CcSEcCtD
Crizotinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000102	0.000702	CcSEcCtD
Crizotinib—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000102	0.0007	CcSEcCtD
Crizotinib—Dizziness—Valsartan—type 2 diabetes mellitus	0.0001	0.000687	CcSEcCtD
Crizotinib—Dizziness—Orlistat—type 2 diabetes mellitus	9.89e-05	0.000679	CcSEcCtD
Crizotinib—Asthenia—Metformin—type 2 diabetes mellitus	9.89e-05	0.000679	CcSEcCtD
Crizotinib—Nausea—Gliclazide—type 2 diabetes mellitus	9.79e-05	0.000671	CcSEcCtD
Crizotinib—Body temperature increased—Losartan—type 2 diabetes mellitus	9.68e-05	0.000664	CcSEcCtD
Crizotinib—CYP3A5—kidney—type 2 diabetes mellitus	9.64e-05	0.000924	CbGeAlD
Crizotinib—Vomiting—Valsartan—type 2 diabetes mellitus	9.62e-05	0.00066	CcSEcCtD
Crizotinib—CYP3A5—pancreas—type 2 diabetes mellitus	9.58e-05	0.000918	CbGeAlD
Crizotinib—Rash—Valsartan—type 2 diabetes mellitus	9.54e-05	0.000655	CcSEcCtD
Crizotinib—Dermatitis—Valsartan—type 2 diabetes mellitus	9.54e-05	0.000654	CcSEcCtD
Crizotinib—Vomiting—Orlistat—type 2 diabetes mellitus	9.51e-05	0.000652	CcSEcCtD
Crizotinib—Diarrhoea—Metformin—type 2 diabetes mellitus	9.43e-05	0.000647	CcSEcCtD
Crizotinib—Rash—Orlistat—type 2 diabetes mellitus	9.43e-05	0.000647	CcSEcCtD
Crizotinib—Paraesthesia—Ramipril—type 2 diabetes mellitus	9.43e-05	0.000647	CcSEcCtD
Crizotinib—Dermatitis—Orlistat—type 2 diabetes mellitus	9.42e-05	0.000646	CcSEcCtD
Crizotinib—CYP3A5—cortex of kidney—type 2 diabetes mellitus	9.39e-05	0.0009	CbGeAlD
Crizotinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	9.36e-05	0.000642	CcSEcCtD
Crizotinib—Asthenia—Irbesartan—type 2 diabetes mellitus	9.33e-05	0.00064	CcSEcCtD
Crizotinib—Dyspepsia—Ramipril—type 2 diabetes mellitus	9.24e-05	0.000634	CcSEcCtD
Crizotinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	9.13e-05	0.000626	CcSEcCtD
Crizotinib—Dizziness—Metformin—type 2 diabetes mellitus	9.12e-05	0.000625	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	9.06e-05	0.000622	CcSEcCtD
Crizotinib—Fatigue—Ramipril—type 2 diabetes mellitus	9.05e-05	0.000621	CcSEcCtD
Crizotinib—Nausea—Valsartan—type 2 diabetes mellitus	8.99e-05	0.000617	CcSEcCtD
Crizotinib—Constipation—Ramipril—type 2 diabetes mellitus	8.98e-05	0.000616	CcSEcCtD
Crizotinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	8.9e-05	0.000611	CcSEcCtD
Crizotinib—Nausea—Orlistat—type 2 diabetes mellitus	8.88e-05	0.00061	CcSEcCtD
Crizotinib—Asthenia—Losartan—type 2 diabetes mellitus	8.78e-05	0.000603	CcSEcCtD
Crizotinib—Vomiting—Metformin—type 2 diabetes mellitus	8.76e-05	0.000601	CcSEcCtD
Crizotinib—Rash—Metformin—type 2 diabetes mellitus	8.69e-05	0.000596	CcSEcCtD
Crizotinib—CYP3A5—adipose tissue—type 2 diabetes mellitus	8.69e-05	0.000833	CbGeAlD
Crizotinib—Dermatitis—Metformin—type 2 diabetes mellitus	8.68e-05	0.000596	CcSEcCtD
Crizotinib—Dizziness—Irbesartan—type 2 diabetes mellitus	8.6e-05	0.00059	CcSEcCtD
Crizotinib—Diarrhoea—Losartan—type 2 diabetes mellitus	8.38e-05	0.000575	CcSEcCtD
Crizotinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	8.3e-05	0.000569	CcSEcCtD
Crizotinib—Vomiting—Irbesartan—type 2 diabetes mellitus	8.27e-05	0.000567	CcSEcCtD
Crizotinib—Rash—Irbesartan—type 2 diabetes mellitus	8.2e-05	0.000563	CcSEcCtD
Crizotinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	8.19e-05	0.000562	CcSEcCtD
Crizotinib—Nausea—Metformin—type 2 diabetes mellitus	8.19e-05	0.000562	CcSEcCtD
Crizotinib—Dizziness—Losartan—type 2 diabetes mellitus	8.1e-05	0.000555	CcSEcCtD
Crizotinib—Vomiting—Losartan—type 2 diabetes mellitus	7.78e-05	0.000534	CcSEcCtD
Crizotinib—Nausea—Irbesartan—type 2 diabetes mellitus	7.73e-05	0.00053	CcSEcCtD
Crizotinib—Rash—Losartan—type 2 diabetes mellitus	7.72e-05	0.00053	CcSEcCtD
Crizotinib—Dermatitis—Losartan—type 2 diabetes mellitus	7.71e-05	0.000529	CcSEcCtD
Crizotinib—Asthenia—Ramipril—type 2 diabetes mellitus	7.53e-05	0.000517	CcSEcCtD
Crizotinib—Nausea—Losartan—type 2 diabetes mellitus	7.27e-05	0.000499	CcSEcCtD
Crizotinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	7.24e-05	0.000694	CbGeAlD
Crizotinib—CYP3A4—kidney—type 2 diabetes mellitus	7.23e-05	0.000693	CbGeAlD
Crizotinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	7.18e-05	0.000493	CcSEcCtD
Crizotinib—Dizziness—Ramipril—type 2 diabetes mellitus	6.94e-05	0.000476	CcSEcCtD
Crizotinib—Vomiting—Ramipril—type 2 diabetes mellitus	6.67e-05	0.000458	CcSEcCtD
Crizotinib—Rash—Ramipril—type 2 diabetes mellitus	6.62e-05	0.000454	CcSEcCtD
Crizotinib—Dermatitis—Ramipril—type 2 diabetes mellitus	6.61e-05	0.000454	CcSEcCtD
Crizotinib—Nausea—Ramipril—type 2 diabetes mellitus	6.24e-05	0.000428	CcSEcCtD
Crizotinib—ABCB1—retina—type 2 diabetes mellitus	6.19e-05	0.000593	CbGeAlD
Crizotinib—CYP3A5—liver—type 2 diabetes mellitus	6.09e-05	0.000584	CbGeAlD
Crizotinib—ABCB1—nephron tubule—type 2 diabetes mellitus	5.83e-05	0.000558	CbGeAlD
Crizotinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	5.23e-05	0.000502	CbGeAlD
Crizotinib—ABCB1—kidney—type 2 diabetes mellitus	5.12e-05	0.000491	CbGeAlD
Crizotinib—ABCB1—pancreas—type 2 diabetes mellitus	5.09e-05	0.000488	CbGeAlD
Crizotinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	4.99e-05	0.000478	CbGeAlD
Crizotinib—ABCB1—adipose tissue—type 2 diabetes mellitus	4.62e-05	0.000442	CbGeAlD
Crizotinib—CYP3A4—liver—type 2 diabetes mellitus	4.57e-05	0.000438	CbGeAlD
Crizotinib—ABCB1—liver—type 2 diabetes mellitus	3.24e-05	0.00031	CbGeAlD
Crizotinib—YES1—Immune System—IL6—type 2 diabetes mellitus	8.56e-07	4.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.55e-07	4.65e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.54e-07	4.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.54e-07	4.65e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CD36—type 2 diabetes mellitus	8.53e-07	4.64e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.51e-07	4.63e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	8.51e-07	4.63e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.45e-07	4.6e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPP2CA—type 2 diabetes mellitus	8.42e-07	4.58e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.36e-07	4.55e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—NFKB1—type 2 diabetes mellitus	8.33e-07	4.53e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SRC—type 2 diabetes mellitus	8.33e-07	4.53e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—type 2 diabetes mellitus	8.31e-07	4.52e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—type 2 diabetes mellitus	8.3e-07	4.52e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—type 2 diabetes mellitus	8.29e-07	4.51e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.28e-07	4.5e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.28e-07	4.5e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—type 2 diabetes mellitus	8.27e-07	4.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	8.25e-07	4.49e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.22e-07	4.47e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SRC—type 2 diabetes mellitus	8.22e-07	4.47e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.2e-07	4.46e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.2e-07	4.46e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AGT—type 2 diabetes mellitus	8.19e-07	4.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—SRC—type 2 diabetes mellitus	8.19e-07	4.45e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—type 2 diabetes mellitus	8.15e-07	4.43e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—type 2 diabetes mellitus	8.12e-07	4.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.12e-07	4.42e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.12e-07	4.42e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.11e-07	4.41e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.08e-07	4.4e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	8.08e-07	4.39e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.05e-07	4.38e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—type 2 diabetes mellitus	8.02e-07	4.36e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LEP—type 2 diabetes mellitus	8.02e-07	4.36e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—type 2 diabetes mellitus	8.02e-07	4.36e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—type 2 diabetes mellitus	8.01e-07	4.35e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8e-07	4.35e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.96e-07	4.33e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—type 2 diabetes mellitus	7.96e-07	4.33e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—type 2 diabetes mellitus	7.95e-07	4.32e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.93e-07	4.31e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	7.93e-07	4.31e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—type 2 diabetes mellitus	7.9e-07	4.29e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—type 2 diabetes mellitus	7.88e-07	4.29e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—type 2 diabetes mellitus	7.85e-07	4.27e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RELA—type 2 diabetes mellitus	7.8e-07	4.24e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SRC—type 2 diabetes mellitus	7.79e-07	4.24e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—type 2 diabetes mellitus	7.77e-07	4.23e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—SRC—type 2 diabetes mellitus	7.77e-07	4.22e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.75e-07	4.22e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.75e-07	4.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—INS—type 2 diabetes mellitus	7.74e-07	4.21e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	7.68e-07	4.17e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	7.67e-07	4.17e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.62e-07	4.14e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.59e-07	4.13e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SRC—type 2 diabetes mellitus	7.56e-07	4.11e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.56e-07	4.11e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	7.55e-07	4.11e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	7.52e-07	4.09e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—type 2 diabetes mellitus	7.49e-07	4.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.49e-07	4.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.48e-07	4.07e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.45e-07	4.05e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.44e-07	4.04e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	7.44e-07	4.04e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	7.44e-07	4.04e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	7.4e-07	4.03e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.4e-07	4.03e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NFKB1—type 2 diabetes mellitus	7.38e-07	4.01e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.37e-07	4.01e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.34e-07	3.99e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—type 2 diabetes mellitus	7.34e-07	3.99e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—type 2 diabetes mellitus	7.32e-07	3.98e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	7.3e-07	3.97e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.3e-07	3.97e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RELA—type 2 diabetes mellitus	7.3e-07	3.97e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—type 2 diabetes mellitus	7.28e-07	3.96e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—type 2 diabetes mellitus	7.27e-07	3.95e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.2e-07	3.92e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—type 2 diabetes mellitus	7.18e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—SRC—type 2 diabetes mellitus	7.17e-07	3.9e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	7.16e-07	3.89e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.16e-07	3.89e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—type 2 diabetes mellitus	7.15e-07	3.89e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.11e-07	3.87e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	7.09e-07	3.86e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—type 2 diabetes mellitus	7.05e-07	3.83e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—type 2 diabetes mellitus	7.04e-07	3.83e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.03e-07	3.82e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	7.01e-07	3.82e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	7.01e-07	3.82e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.97e-07	3.79e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	6.9e-07	3.75e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	6.88e-07	3.74e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INS—type 2 diabetes mellitus	6.85e-07	3.73e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	6.84e-07	3.72e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	6.84e-07	3.72e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	6.84e-07	3.72e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.83e-07	3.71e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—type 2 diabetes mellitus	6.81e-07	3.7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	6.79e-07	3.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.79e-07	3.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.79e-07	3.69e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	6.77e-07	3.68e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.76e-07	3.68e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.75e-07	3.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.74e-07	3.67e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—type 2 diabetes mellitus	6.71e-07	3.65e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	6.67e-07	3.63e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.64e-07	3.61e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.64e-07	3.61e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.63e-07	3.61e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	6.63e-07	3.61e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.63e-07	3.6e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.62e-07	3.6e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	6.61e-07	3.59e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.6e-07	3.59e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	6.6e-07	3.59e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.58e-07	3.58e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.57e-07	3.58e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	6.55e-07	3.56e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.54e-07	3.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.54e-07	3.56e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.5e-07	3.54e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	6.43e-07	3.5e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	6.43e-07	3.49e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—type 2 diabetes mellitus	6.41e-07	3.49e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	6.39e-07	3.48e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—type 2 diabetes mellitus	6.38e-07	3.47e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	6.35e-07	3.46e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—type 2 diabetes mellitus	6.35e-07	3.46e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.29e-07	3.42e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—type 2 diabetes mellitus	6.28e-07	3.42e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.22e-07	3.38e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.22e-07	3.38e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.15e-07	3.35e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	6.13e-07	3.33e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	6.13e-07	3.33e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	6.13e-07	3.33e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—type 2 diabetes mellitus	6.13e-07	3.33e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	6.1e-07	3.32e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.03e-07	3.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.03e-07	3.28e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—type 2 diabetes mellitus	6.03e-07	3.28e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	6.02e-07	3.27e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.01e-07	3.27e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.01e-07	3.27e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	5.98e-07	3.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—type 2 diabetes mellitus	5.97e-07	3.25e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.97e-07	3.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.96e-07	3.24e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	5.89e-07	3.2e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—type 2 diabetes mellitus	5.89e-07	3.2e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	5.86e-07	3.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.84e-07	3.17e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	5.79e-07	3.15e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.76e-07	3.13e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—type 2 diabetes mellitus	5.73e-07	3.12e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	5.7e-07	3.1e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	5.68e-07	3.09e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—type 2 diabetes mellitus	5.67e-07	3.09e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RELA—type 2 diabetes mellitus	5.66e-07	3.08e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	5.63e-07	3.06e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	5.63e-07	3.06e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.61e-07	3.05e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	5.61e-07	3.05e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.61e-07	3.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.58e-07	3.04e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—type 2 diabetes mellitus	5.56e-07	3.03e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	5.54e-07	3.02e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	5.54e-07	3.02e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.53e-07	3.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—type 2 diabetes mellitus	5.51e-07	3e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—type 2 diabetes mellitus	5.51e-07	3e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.48e-07	2.98e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.45e-07	2.96e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.39e-07	2.93e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.37e-07	2.92e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	5.32e-07	2.89e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	5.32e-07	2.89e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.25e-07	2.85e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—type 2 diabetes mellitus	5.23e-07	2.85e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.18e-07	2.82e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	5.15e-07	2.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.12e-07	2.79e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.11e-07	2.78e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.1e-07	2.77e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.1e-07	2.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—type 2 diabetes mellitus	5.09e-07	2.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.02e-07	2.73e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	5.02e-07	2.73e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	4.94e-07	2.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.89e-07	2.66e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	4.85e-07	2.64e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.84e-07	2.63e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—type 2 diabetes mellitus	4.83e-07	2.63e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—type 2 diabetes mellitus	4.83e-07	2.62e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.82e-07	2.62e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.77e-07	2.59e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.7e-07	2.56e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—type 2 diabetes mellitus	4.63e-07	2.52e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.58e-07	2.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.58e-07	2.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.56e-07	2.48e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.5e-07	2.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.49e-07	2.44e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—type 2 diabetes mellitus	4.46e-07	2.42e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	4.45e-07	2.42e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.4e-07	2.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	4.37e-07	2.38e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.33e-07	2.35e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—type 2 diabetes mellitus	4.28e-07	2.33e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—type 2 diabetes mellitus	4.27e-07	2.32e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	4.25e-07	2.31e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	4.25e-07	2.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.25e-07	2.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.17e-07	2.27e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—type 2 diabetes mellitus	4.13e-07	2.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	4.08e-07	2.22e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	4.07e-07	2.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.97e-07	2.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.96e-07	2.16e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—type 2 diabetes mellitus	3.94e-07	2.15e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.91e-07	2.13e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.9e-07	2.12e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	3.89e-07	2.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—type 2 diabetes mellitus	3.86e-07	2.1e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.81e-07	2.07e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.76e-07	2.04e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.68e-07	2e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.57e-07	1.94e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.56e-07	1.94e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.51e-07	1.91e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.5e-07	1.9e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.46e-07	1.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	3.38e-07	1.84e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.12e-07	1.7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.05e-07	1.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—type 2 diabetes mellitus	2.99e-07	1.63e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.99e-07	1.62e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.76e-07	1.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.74e-07	1.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.62e-07	1.42e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.62e-07	1.42e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	2.59e-07	1.41e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.4e-07	1.3e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	1.95e-07	1.06e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.2e-07	6.55e-07	CbGpPWpGaD
